AMYLOIDOSIS WITH LIGHT CHAIN DEPOSITION CARDIOMYOPATHY: A CLINICAL CASE STUDY
Main Article Content
Abstract
Light chain cardiac amyloidosis (AL-CA) is a disease caused by the accumulation of amyloid fibers in the heart muscle, formed due to the abnormal proliferation of plasma cells. This is one of the causes of heart failure, especially in heart failure with preserved ejection fraction, which clinicians need to identify and diagnose early because symptoms are nonspecific, and the prognosis is often poor if diagnosed late. We present a case of hospital admission for heart failure with preserved ejection fraction that exhibited several features suggestive of amyloidosis in clinical and imaging findings. The patient underwent additional tests to confirm the diagnosis and received initial in-hospital chemotherapy. This is a fairly typical case of light chain cardiac amyloidosis that we may encounter in clinical practice.
Article Details
References
2. Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. Mar 21 2023;81(11):1076-1126. doi:10.1016/j.jacc.2022.11.022
3. Wechalekar Ashutosh D, Fontana M, Quarta CC, Liedtke M. AL Amyloidosis for Cardiologists. JACC: CardioOncology. 2022/11/01 2022; 4(4) :427-441. doi:10.1016/j.jaccao.2022.08.009
4. Oubari S, Naser E, Papathanasiou M, et al. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. European Journal of Haematology. 2021/10/01 2021; 107(4): 449-457. doi: https://doi.org/10.1111/ ejh.13681
5. Frederick L Ruberg MSM. Cardiac Amyloidosis. In: Braunwald PLROBDLMGFTDLBSDSE, ed. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine 12th Edition. Elsevier; 2022:1052-1060.
6. Kyrouac D, Schiffer W, Lennep B, et al. Echocardiographic and clinical predictors of cardiac amyloidosis: limitations of apical sparing. ESC heart failure. Feb 2022;9(1):385-397. doi: 10.1002/ehf2.13738
7. Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nature reviews Disease primers. Oct 25 2018;4(1):38. doi:10.1038/s41572-018-0034-3
8. Kyriakou P, Mouselimis D, Tsarouchas A, et al. Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers. BMC Cardiovascular Disorders. 2018/12/04 2018;18(1):221. doi:10.1186/s12872-018-0952-8